FDA requires strong amputation warning on sedative

Sep 16, 2009 By LINDA A. JOHNSON , AP Business Writer

(AP) -- Makers of injected promethazine, a sedative also used to treat nausea and vomiting, are being required to put the strongest warning possible on the product because it can cause tissue damage leading to amputation, the Food and Drug Administration said Wednesday.

The drug, previously sold by Wyeth Pharmaceuticals Inc. under the brand name Phenergan, was at the heart of a U.S. Supreme Court case this spring that ended in a ruling that consumers harmed by a medication approved by the FDA still have the right to sue the manufacturer.

Wyeth had appealed the case up to the Supreme Court after a Vermont woman named Diana Levine, who once played the guitar and piano professionally, sued because she had to have her right arm amputated after being injected with Phenergan. Levine's lawsuit, which claimed she wasn't sufficiently warned of the risks of using Phenergan, won her a $6.7 million jury award.

The FDA said Wednesday that makers of generic promethazine will have to put a "black box" warning at the top of the detailed package insert explaining that when the drug is administered incorrectly, it can damage skin severely, including causing gangrene.

The FDA said promethazine should be injected deep into muscle, never into an artery or under the skin and, when given intravenously, it should be done slowly and at a low concentration. That's because the drug can leach out of a vein and seriously damage surrounding tissue.

Companies will have 30 days to provide the FDA with acceptable wording for the package insert. Otherwise, the FDA can order changes it deems appropriate.

The warning, which already is in the package insert but not highlighted in a box outlined in black, also is being sent to doctors.

Promethazine has been on the market since 1956. FDA said reports and medical literature and reports the agency received about side effects from the drug showed it has been linked to an unspecified number of gangrene cases requiring .

In a 6-3 decision in March, the Supreme Court rejected Wyeth's claim that federal approval of Phenergan and its warning label should have shielded the company from lawsuits like Levine's.

Prior to that, business groups had aggressively pushed for such limits on lawsuits through the doctrine of "pre-emption" - the idea that federal regulation trumps rules that might differ from state to state.

The Supreme Court had largely agreed, ruling in the prior term that FDA approval shields medical devices from most lawsuits.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: FDA approves hard-to-abuse narcotic painkiller

add to favorites email to friend print save as pdf

Related Stories

Mayo Clinic questions FDA drug warning

Oct 01, 2007

A Mayo Clinic study has brought into question a U.S. Food and Drug Administration warning about the use of a medication to control nausea during surgery.

FDA issues bismacine-chromacine warning

Jul 24, 2006

The U.S. Food and Drug Administration is warning consumers and healthcare providers not to use a product called bismacine, also known as chromacine.

FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

FDA acts against unapproved colchicine

Feb 06, 2008

The U.S. Food and Drug Administration said it will take action against companies marketing unapproved injectable colchicine, a drug used to treat gout.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0